Yann Godbert

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.

Real-World Outcomes of [177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: April 13, 2026

ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.

ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.

Journal: Annales d'endocrinologie

Published: April 07, 2025

ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.

ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.

Journal: Annales d'endocrinologie

Published: April 06, 2025

Title Not Found

Title Not Found

Journal: Bulletin du cancer

Published: November 06, 2024

Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma.

Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma.

Journal: Clinical nuclear medicine

Published: November 06, 2024

Title Not Found

Title Not Found

Journal: Bulletin du cancer

Published: November 06, 2024

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial.

Journal: The lancet. Diabetes & endocrinology

Published: June 14, 2024

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF).

Journal: Frontiers in endocrinology

Published: March 19, 2024

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.

Journal: Thyroid : official journal of the American Thyroid Association

Published: November 27, 2023

Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center.

Evaluating video-based consultations in routine clinical practice at a comprehensive cancer center.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 10, 2023

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.

Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.

Journal: Thyroid : official journal of the American Thyroid Association

Published: October 19, 2023

Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

Correction: ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.

Journal: Trials

Published: July 11, 2023

Showing 1-12 of 45

Last Updated: 09/26/2026